A Phase II Study of the mTOR Inhibitor Sirolimus in Neurofibromatosis Type 1 Related Plexiform Neurofibromas (Protocol 102)

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Children's Hospital Boston
Children's Hospital of Philadelphia
Children's Research Institute
Children's Hospital Medical Center, Cincinnati
University of Chicago
University of Utah
Washington University
Information provided by (Responsible Party):
University of Alabama at Birmingham
ClinicalTrials.gov Identifier:
NCT00634270
First received: February 20, 2008
Last updated: March 14, 2014
Last verified: February 2014
No Study Results Posted on ClinicalTrials.gov for this Study
  Study Status: This study is ongoing, but not recruiting participants.
  Estimated Study Completion Date: August 2014
  Estimated Primary Completion Date: August 2014 (Final data collection date for primary outcome measure)